Performance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare Setting in Cape Town, South Africa
Open Access
- 13 October 2025
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (11) , e70095
Abstract
Improved HCV diagnosis and linkage to care is crucial to achieve WHO 2030 elimination targets. Simplification of diagnostics remains key. We evaluated the performance of Elecsys HCV Duo antigen/antibody immunoassay in patients using public healthcare in Cape Town, South Africa. 253 HCV seropositive and 214 seronegative samples were tested, and results correlated with standard‐of‐care (SOC) serology, HCV RNA, viral genotype, patient demographics, and disease markers. Thirteen patients on antiviral therapy were also evaluated. Elecsys HCV Duo antibody was equivalent to SOC serology, while antigen had 100% negative percent agreement in non‐viraemic samples. One incident infection with viral load (VL) of 54,000 IU/mL was antigen positive/antibody negative. Overall, antigen detection was 63.2% in RNA‐positive samples. VL strongly predicted reactivity, with antigen positive rates of 17.5% (< 5 log IU/mL), 75.8% (5–6 log IU/mL), 89.4% (6–7 log IU/mL), and 100% (> 7 log IU/mL). Detection in genotype‐1 infections was significantly better, at 69.6% (95% CI 59.5–79.7) than non‐genotype‐1 at 43.2% (95% CI 28.7–57.7). In treated patients, antigen mirrored RNA clearance but was only reliable if positive at baseline. Elecsys HCV Duo detected active infection in 63% of viraemic patients, 70% with genotype 1. In our cohort, 49% of new patients would require VL testing.Keywords
This publication has 9 references indexed in Scilit:
- Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatmentPLOS ONE, 2024
- Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testingJournal of Clinical Microbiology, 2024
- An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNAPLOS ONE, 2023
- Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta‐analysisReviews in Medical Virology, 2023
- Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAsPLOS ONE, 2023
- Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free futureArab Journal of Gastroenterology, 2021
- Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotypeJournal of Viral Hepatitis, 2020
- Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South AfricaSouth African Medical Journal, 2020
- Hepatitis CThe Lancet, 2019